Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,374 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Management of carcinoma of the penis: Consensus statement from the Canadian Association of Genitourinary Medical Oncologists (CAGMO).
Richter S, Ruether JD, Wood L, Canil C, Moretto P, Venner P, Gingerich J, Emmenegger U, Eisen A, Zalewski P, Joshua A, Mukherjee SD, Heng D, Czaykowski P, Soulieres D, Blais N, Rendon R, Fleshner N, Crook JM, Sridhar SS. Richter S, et al. Among authors: wood l. Can Urol Assoc J. 2013 Nov-Dec;7(11-12):E797-811. doi: 10.5489/cuaj.1794. Can Urol Assoc J. 2013. PMID: 24475001 Free PMC article. No abstract available.
Canadian consensus guidelines for the management of testicular germ cell cancer.
Wood L, Kollmannsberger C, Jewett M, Chung P, Hotte S, O'Malley M, Sweet J, Anson-Cartwright L, Winquist E, North S, Tyldesley S, Sturgeon J, Gospodarowicz M, Segal R, Cheng T, Venner P, Moore M, Albers P, Huddart R, Nichols C, Warde P. Wood L, et al. Can Urol Assoc J. 2010 Apr;4(2):e19-38. doi: 10.5489/cuaj.815. Can Urol Assoc J. 2010. PMID: 20368885 Free PMC article. No abstract available.
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
Saad F, Hotte S, North S, Eigl B, Chi K, Czaykowski P, Wood L, Pollak M, Berry S, Lattouf JB, Mukherjee SD, Gleave M, Winquist E; Canadian Uro-Oncology Group. Saad F, et al. Among authors: wood l. Clin Cancer Res. 2011 Sep 1;17(17):5765-73. doi: 10.1158/1078-0432.CCR-11-0859. Epub 2011 Jul 25. Clin Cancer Res. 2011. PMID: 21788353 Clinical Trial.
Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma.
Hotte SJ, Bjarnason GA, Heng DY, Jewett MA, Kapoor A, Kollmannsberger C, Maroun J, Mayhew LA, North S, Reaume MN, Ruether JD, Soulieres D, Venner PM, Winquist EW, Wood L, Yong JH, Saad F. Hotte SJ, et al. Among authors: wood l. Curr Oncol. 2011 Oct;18 Suppl 2(Suppl 2):S11-9. Curr Oncol. 2011. PMID: 21969807 Free PMC article.
2,374 results